Jan Malcolm Sells 50 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Jan Malcolm sold 50 shares of the business’s stock in a transaction dated Tuesday, December 23rd. The stock was sold at an average price of $512.12, for a total transaction of $25,606.00. Following the sale, the director directly owned 420 shares in the company, valued at $215,090.40. This trade represents a 10.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Jan Malcolm also recently made the following trade(s):

• On Thursday, December 11th, Jan Malcolm sold 50 shares of United Therapeutics stock. The shares were sold at an average price of $482.98, for a total value of $24,149.00.

United Therapeutics Stock Down 0.7%

Shares of NASDAQ:UTHR traded down $3.35 during midday trading on Tuesday, reaching $510.44. The company had a trading volume of 382,700 shares, compared to its average volume of 581,627. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $519.99. The stock has a market cap of $21.98 billion, a PE ratio of 19.34, a P/E/G ratio of 5.13 and a beta of 0.86. The business’s 50 day moving average price is $465.10 and its 200 day moving average price is $382.72.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. During the same period last year, the company earned $6.39 earnings per share. The business’s revenue was up 6.8% compared to the same quarter last year. On average, research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in UTHR. American Century Companies Inc. boosted its stake in United Therapeutics by 0.4% in the 1st quarter. American Century Companies Inc. now owns 38,320 shares of the biotechnology company’s stock valued at $11,813,000 after purchasing an additional 168 shares during the period. Raymond James Financial Inc. boosted its position in shares of United Therapeutics by 7.3% in the first quarter. Raymond James Financial Inc. now owns 55,545 shares of the biotechnology company’s stock valued at $17,123,000 after acquiring an additional 3,801 shares during the period. Quantbot Technologies LP boosted its position in shares of United Therapeutics by 5,072.2% in the first quarter. Quantbot Technologies LP now owns 1,862 shares of the biotechnology company’s stock valued at $574,000 after acquiring an additional 1,826 shares during the period. Allstate Corp grew its stake in shares of United Therapeutics by 64.1% in the first quarter. Allstate Corp now owns 1,930 shares of the biotechnology company’s stock valued at $595,000 after acquiring an additional 754 shares in the last quarter. Finally, SVB Wealth LLC acquired a new stake in United Therapeutics in the 1st quarter worth about $32,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on UTHR shares. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Monday. Royal Bank Of Canada lifted their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. UBS Group upped their target price on shares of United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Oppenheimer lifted their price target on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. Finally, Bank of America boosted their price target on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 2nd. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $505.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.